Quest Laboratories Limited (NSE:QUESTLAB)
India · Delayed Price · Currency is INR 93.50
+0.90 (0.97%)
Oct 7, 2026, 3:18 PM IST
Quest Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,118 | 1,040 | 825.63 | 616.41 | 594.84 |
Other Revenue | - | 0 | - | - | - |
| 1,118 | 1,040 | 825.63 | 616.41 | 594.84 | |
Revenue Growth | 7.56% | 25.92% | 33.94% | 3.63% | 95.91% |
Cost of Revenue | 875.35 | 806.14 | 537.74 | 419.24 | 446.19 |
Gross Profit | 242.87 | 233.52 | 287.89 | 197.17 | 148.65 |
Selling, General & Admin | 47.64 | 43.27 | 45.03 | 33.59 | 34.77 |
Other Operating Expenses | 11.29 | 13.57 | 87.22 | 83.9 | 48.78 |
Operating Expenses | 67.17 | 62.07 | 137.93 | 122.98 | 88.15 |
Operating Income | 175.7 | 171.44 | 149.96 | 74.19 | 60.5 |
Interest Expense | -17.63 | -8.43 | -7.2 | -5.06 | -2.73 |
Interest & Investment Income | 22.45 | 25.92 | 2.29 | 0.98 | 0.39 |
Other Non Operating Income (Expenses) | -0.91 | -0.63 | -0.59 | -0.32 | -0.23 |
EBT Excluding Unusual Items | 179.61 | 188.3 | 144.46 | 69.78 | 57.93 |
Gain (Loss) on Sale of Assets | - | - | - | 0.04 | -0.26 |
Pretax Income | 179.61 | 188.3 | 144.46 | 69.82 | 57.67 |
Income Tax Expense | 30.89 | 51.18 | 43.52 | 19.37 | 16.62 |
Net Income | 148.71 | 137.12 | 100.94 | 50.45 | 41.05 |
Net Income to Common | 148.71 | 137.12 | 100.94 | 50.45 | 41.05 |
Net Income Growth | 8.45% | 35.85% | 100.08% | 22.90% | 527.01% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 11 | 11 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 11 | 11 |
Shares Change | - | - | 51.91% | - | - |
EPS (Basic) | 9.08 | 8.37 | 6.16 | 4.68 | 3.81 |
EPS (Diluted) | 9.07 | 8.37 | 6.16 | 4.68 | 3.81 |
EPS Growth | 8.39% | 35.85% | 31.73% | 22.88% | 527.01% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -159.76 | -232.93 | 20.73 | 8.66 | 15.24 |
Free Cash Flow Per Share | -9.75 | -14.21 | 1.26 | 0.80 | 1.41 |
Gross Margin | 21.72% | 22.46% | 34.87% | 31.99% | 24.99% |
Operating Margin | 15.71% | 16.49% | 18.16% | 12.04% | 10.17% |
Profit Margin | 13.30% | 13.19% | 12.23% | 8.18% | 6.90% |
Free Cash Flow Margin | -14.29% | -22.40% | 2.51% | 1.41% | 2.56% |
EBITDA | 183.94 | 176.67 | 155.64 | 79.68 | 65.1 |
EBITDA Margin | 16.45% | 16.99% | 18.85% | 12.93% | 10.95% |
D&A For EBITDA | 8.25 | 5.23 | 5.68 | 5.5 | 4.6 |
EBIT | 175.7 | 171.44 | 149.96 | 74.19 | 60.5 |
EBIT Margin | 15.71% | 16.49% | 18.16% | 12.04% | 10.17% |
Effective Tax Rate | 17.20% | 27.18% | 30.13% | 27.74% | 28.82% |
Revenue as Reported | 1,142 | 1,082 | 827.92 | 618.66 | 595.42 |
Advertising Expenses | 0.06 | 0.44 | 0.18 | 0.04 | 0.01 |